Testing whether a smartwatch can catch early warning signs in people with leptomeningeal metastasis
Official title: Wearable-Triggered Digital Safety Net for Real-Time Monitoring & Intervention in Leptomeningeal Metastasis
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests whether a smartwatch can notice early signs of trouble and alert a person's doctor right away.
Read our full plain-language summary
What the trial team says
This research study is for participants diagnosed with leptomeningeal metastasis disease (LMM), a condition where cancer has spread to the fluid and membranes surround the brain and spinal cord. The purpose of this study is to find out whether a consumer Smartwatch can continuously monitor the participant's health and detect early signs of neurological decline and whether sending an automatic alert to the participant's doctor when a change is detected can help reduce the number of participant hospitalizations.
Key facts
- Registry number
- NCT07704034
- Stage of testing
- Not applicable
- Conditions studied
- Leptomeningeal Metastasis
Where it is running
This trial lists 1 site.
-
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center (Cleveland)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.